Clinical Trial Update: Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating erythropoietin after revascularization in myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Deutsches Herzzentrum Muenchen | Conditions: Myocardial Infarction, Angioplasty, Transluminal, Percutaneous Coronary | Phase 3 | Status: COMPLETED